ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: 1774

Making Decisions About Medication Use, Pregnancy, and Having Children Among Women with Rheumatoid Arthritis: A Constructivist Grounded Theory Study

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1628

Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)

Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

9:00AM-11:00AM: Abstract Number: 1629

Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)

Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

9:00AM-11:00AM: Abstract Number: 1780

Maternal and Fetal Outcomes in Pregnant Women with Psoriatic Arthritis: A Systematic Literature Review

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1767

Maternal Peripartum Outcomes Are Similar to the General Population in Rheumatoid Arthritis Pregnancies

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1560

Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1886

Measuring Physical Activity in AxSpA:Content Validity and Measurement Properties of the New AxSpA-SQUASH

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

9:00AM-11:00AM: Abstract Number: 1696

Measuring Quality Improvement from CME Participants: Results from the RAPID® CME Initiative

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1658

Mediation of the Association Between Obesity and Osteoarthritis by Blood Pressure, Arterial Stiffness, and Subclinical Atherosclerosis

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1839

Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1675

Microstructural Damage Is Associated with Age at Disease-onset and Cognitive Impairment in Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1606

Mortality with Idiopathic Inflammatory Myositis in an Academic Hospital Setting: A Five-year Retrospective Study

Measures & Measurement of Healthcare Quality Poster

9:00AM-11:00AM: Abstract Number: 1711

Musculoskeletal Sarcoidosis Learning Module for Internal Medicine Trainees: Developing a Rheumatology Curriculum

Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1823

Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1676

Neuropsychiatric Involvement in Juvenile-onset Systemic Lupus Erythematosus (JSLE): Data from the UK JSLE Cohort Study

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].